Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients

Recruiting now

Conditions studied: Diabetes, Postoperative Delirium

In brief

To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients

Key facts

Study ID

NCT06426953

Run by

Xie Kangjie

People needed

180

Starts

2024-05-20

Expected to finish

2026-08-30

Last updated by the study team

2025-09-29

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥65 years
• History of diabetes ≥2 years and Glycated hemoglobin ≥6.5% or no history of diabetes and normal blood glucose
• The ASA rating is Class I to III
• The elderly patients of limited thoracic and abdominal tumor surgery

You may not qualify if…

• Refused to participate
• Previous history of schizophrenia, epilepsy, Parkinson's disease
• History of alcohol abuse or drug dependence
• Patients with ASA grade IV and above
• Severe visual or hearing impairment, can not cooperate with the completion of cognitive function tests
• Participants in other clinical trials within the last two months
• Patients with severe arrhythmia or cardiac dysfunction(EF<40%)
• There was a clear history of neurological and psychiatric problems or long-term use of sedatives or antidepressants
• History of cerebrovascular disease or brain surgery or trauma
• Severe liver dysfunction (Child-Pugh class C) or severe renal dysfunction (requiring dialysis)

Where it is running

• Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (enrolling)
• The People's hospital of Qiannan — Duyun, Guizhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.